Clinical trial
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk…
NCT00058526 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00058526 |
|---|---|
| Title | A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer |
| Official title | A Multicenter Phase I Open-label Dose-escalation Vaccine Trial of dHER2 Protein With AS15 Adjuvant in HER2-overexpressing Patients With High-risk Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Biological |
| Interventions | Immunotherapeutic SB719125 (Primary) |
| Enrollment | 61 |
| Start date | Mar 20, 2003 |
| Primary completion | Sep 6, 2006 |
| Completion | Sep 6, 2006 |
| First posted | Apr 9, 2003 |
| Last update posted | May 15, 2017 |
| Countries | Australia, Belgium, France, Italy, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: